Fawzy, M., Mosbah, A., zalata, K., Shebl, A. (2016). Predictors of progestin therapy response in endometrial hyperplasia: An immunohistochemical study. test, 20(2), 6-11. doi: 10.21608/egyfs.2016.19528
Muhammad Fawzy; Alaa Mosbah; Khaled zalata; Abdelhadi Shebl. "Predictors of progestin therapy response in endometrial hyperplasia: An immunohistochemical study". test, 20, 2, 2016, 6-11. doi: 10.21608/egyfs.2016.19528
Fawzy, M., Mosbah, A., zalata, K., Shebl, A. (2016). 'Predictors of progestin therapy response in endometrial hyperplasia: An immunohistochemical study', test, 20(2), pp. 6-11. doi: 10.21608/egyfs.2016.19528
Fawzy, M., Mosbah, A., zalata, K., Shebl, A. Predictors of progestin therapy response in endometrial hyperplasia: An immunohistochemical study. test, 2016; 20(2): 6-11. doi: 10.21608/egyfs.2016.19528

Predictors of progestin therapy response in endometrial hyperplasia: An immunohistochemical study

The Egyptian Journal of Fertility and Sterility
Article 2, Volume 20, Issue 2, June 2016, Pages 6-11    PDF (2.6 M)
Document Type: Original Article
DOI: 10.21608/egyfs.2016.19528
Authors
Muhammad Fawzy1; Alaa Mosbah1; Khaled zalata2; Abdelhadi Shebl2
1Department of Obstetrics and Gynecology, Faculty of Medicine, Mansoura University, Egypt.
2Department of Pathology, Faculty of Medicine, Mansoura University, Egypt.
Abstract
Background: Women with endometrial hyperplasia have an elevated risk of endometrial carcinoma .The first line of treatment of endometrial hyperplasia in premenopausal women is progestin treatment with variable response. Objectives: To evaluate the predictive value of immunohistochemical (IHC) biomarkers in progestin treatment for cases having endometrial hyperplasia.
Methods: A prospective trial was conducted among 50 premenopausal women with menometrorrhagia. Histopathological evaluation confirmed endometrial hyperplasia in pre-treatment endometrial biopsy [without atypia (n=43) and atypia (n=7)]. All patients treated with oral progestin for 3-6 months. Endometrial immunohistochemical examination for progesterone receptors, Bel-2 and p53 were analyzed in basal blocks.
Results: Study participants were classified into two groups, Group One showed endometrial response (n = 38) and Group Two showed non-response or histological progression (n=12). Immunohistochemical expression was expressed as a histopathological immunoreactive score (IRS). Immunoreactive score for progesterone receptors were significant higher in responders. Absence of progesterone receptors and presence of p53 predicted non-responder status.
Conclusions: Progesterone receptor expression may be a predictive biomarker of progestin response and p53 expression may be a predictive biomarker of progestin resistance.
Statistics
Article View: 255
PDF Download: 634